| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Article |
Fusion Oncogene in Both Follicular Thyroid Carcinomas and Adenomas
Cancer Genetics Unit, Kolling Institute (L.C., M.M., D.L., J.W., R.C.-B., B.G.R.), and Departments of Surgery (L.D.) and Pathology (A.G., A.C., J.P.), Royal North Shore Hospital, St. Leonards, New South Wales 2065, Australia
Address all correspondence and requests for reprints to: Prof. Bruce G. Robinson, Cancer Genetics Unit, Kolling Institute, Royal North Shore Hospital, St. Leonards, New South Wales 2065, Australia. E-mail: bgr{at}med.usyd.edu.au.
Chromosomal translocations encoding fusion oncoproteins are common in hematological malignancies, sarcomas, and papillary thyroid carcinomas. A recent study of follicular thyroid carcinomas reported a novel chromosomal translocation, t(2;3)(q13;p25), that fused the thyroid-specific transcription factor PAX8 with a nuclear receptor, peroxisome proliferator-activated receptor
(PPAR
). Herein we report the detection of this putative oncoprotein in 6 of 17 (35%) follicular thyroid carcinomas as well as in 6 of 11 (55%) follicular thyroid adenomas. Concordant expression of protein was found in 91% of those tumors in which PAX8-PPAR
mRNA was detected by RT-PCR, whereas a further 20% of follicular tumors were positive for PPAR
immunohistochemistry alone. Our findings suggest that the PAX8-PPAR
fusion protein promotes differentiated follicular thyroid neoplasia, although it is not sufficient per se for carcinogenesis.
This work was supported by grants from The Leo and Jenny Cancer and Leukemia Foundation and the University of Sydney Cancer Research Fund.
L.C. was supported by a Royal North Shore Hospital Westpac postgraduate scholarship.
Abbreviations: FTA, Follicular thyroid adenoma; FTC, follicular thyroid carcinoma; PPAR
, peroxisome proliferator-activated receptor
.
This article has been cited by other articles:
![]() |
M. Eszlinger, K. Krohn, S. Hauptmann, H. Dralle, T. J. Giordano, and R. Paschke Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3286 - 3294. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Y Liu, H. Morreau, J. Kievit, J. A Romijn, N. Carrasco, and J. W Smit Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma Eur. J. Endocrinol., March 1, 2008; 158(3): 375 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Salajegheh, E B Petcu, R A Smith, and A K-Y Lam Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists Postgrad. Med. J., February 1, 2008; 84(988): 78 - 82. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. V. Frau, M. L. Lai, P. Caria, T. Dettori, P. Coni, G. Faa, L. Morandi, G. Tallini, and R. Vanni Trisomy 17 as a Marker for a Subset of Noninvasive Thyroid Nodules with Focal Features of Papillary Carcinoma: Cytogenetic and Molecular Analysis of 62 Cases and Correlation with Histological Findings J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 177 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Eszlinger, K. Krohn, A. Kukulska, B. Jarzab, and R. Paschke Perspectives and Limitations of Microarray-Based Gene Expression Profiling of Thyroid Tumors Endocr. Rev., May 1, 2007; 28(3): 322 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Michalik, J. Auwerx, J. P. Berger, V. K. Chatterjee, C. K. Glass, F. J. Gonzalez, P. A. Grimaldi, T. Kadowaki, M. A. Lazar, S. O'Rahilly, et al. International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors Pharmacol. Rev., December 1, 2006; 58(4): 726 - 741. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Bakhsh, G Kirov, J W Gregory, E D Williams, and M Ludgate A new form of familial multi-nodular goitre with progression to differentiated thyroid cancer. Endocr. Relat. Cancer, June 1, 2006; 13(2): 475 - 483. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Foukakis, A. Y. M. Au, G. Wallin, J. Geli, L. Forsberg, R. Clifton-Bligh, B. G. Robinson, W.-O. Lui, J. Zedenius, and C. Larsson The Ras Effector NORE1A Is Suppressed in Follicular Thyroid Carcinomas with a PAX8-PPAR{gamma} Fusion J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 1143 - 1149. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Castro, A. P. Rebocho, R. J. Soares, J. Magalhaes, L. Roque, V. Trovisco, I. Vieira de Castro, M. Cardoso-de-Oliveira, E. Fonseca, P. Soares, et al. PAX8-PPAR{gamma} Rearrangement Is Frequently Detected in the Follicular Variant of Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 213 - 220. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Y. M. Au, C. McBride, K. G. Wilhelm Jr., R. J. Koenig, B. Speller, L. Cheung, M. Messina, J. Wentworth, V. Tasevski, D. Learoyd, et al. PAX8-Peroxisome Proliferator-Activated Receptor {gamma} (PPAR{gamma}) Disrupts Normal PAX8 or PPAR{gamma} Transcriptional Function and Stimulates Follicular Thyroid Cell Growth Endocrinology, January 1, 2006; 147(1): 367 - 376. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Castro, L. Roque, J. Magalhaes, and M. Sobrinho-Simoes A Subset of the Follicular Variant of Papillary Thyroid Carcinoma Harbors the PAX8-PPAR{gamma} Translocation International Journal of Surgical Pathology, July 1, 2005; 13(3): 235 - 238. [Abstract] [PDF] |
||||
![]() |
L. Lacroix, V. Lazar, S. Michiels, H. Ripoche, P. Dessen, M. Talbot, B. Caillou, J.-P. Levillain, M. Schlumberger, and J.-M. Bidart Follicular Thyroid Tumors with the PAX8-PPAR{gamma}1 Rearrangement Display Characteristic Genetic Alterations Am. J. Pathol., July 1, 2005; 167(1): 223 - 231. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Xing BRAF mutation in thyroid cancer Endocr. Relat. Cancer, June 1, 2005; 12(2): 245 - 262. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sahin, B. L. Allard, M. Yates, J. G. Powell, X.-L. Wang, I. D. Hay, Y. Zhao, J. R. Goellner, T. J. Sebo, S. K. G. Grebe, et al. PPAR{gamma} Staining as a Surrogate for PAX8/PPAR{gamma} Fusion Oncogene Expression in Follicular Neoplasms: Clinicopathological Correlation and Histopathological Diagnostic Value J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 463 - 468. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Xing, R. P. Tufano, A. P. Tufaro, S. Basaria, M. Ewertz, E. Rosenbaum, P. J. Byrne, J. Wang, D. Sidransky, and P. W. Ladenson Detection of BRAF Mutation on Fine Needle Aspiration Biopsy Specimens: A New Diagnostic Tool for Papillary Thyroid Cancer J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2867 - 2872. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Dwight, S. R. Thoppe, T. Foukakis, W. O. Lui, G. Wallin, A. Hoog, T. Frisk, C. Larsson, and J. Zedenius Involvement of the PAX8/Peroxisome Proliferator-Activated Receptor {gamma} Rearrangement in Follicular Thyroid Tumors J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4440 - 4445. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |